DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
4.210
+0.120 (2.93%)
Jun 6, 2025, 2:48 PM - Market open
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
180.54M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DMAC News
- 15 days ago - DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 - Business Wire
- 18 days ago - DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire
- 22 days ago - DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025 - Business Wire
- 23 days ago - DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - Business Wire
- 4 weeks ago - DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May - Business Wire
- 4 weeks ago - DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025 - Business Wire
- 2 months ago - DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript - Seeking Alpha